GT Molecular Enters Cancer Molecular Assay Market
GT Molecular, Inc. is entering the cancer molecular assay market with multi-target PCR kits featuring quality control metrics.
Read MorePosted by Chris Wolski | Jun 1, 2023 | Molecular Diagnostics |
GT Molecular, Inc. is entering the cancer molecular assay market with multi-target PCR kits featuring quality control metrics.
Read MorePosted by Melanie Hamilton-Basich | May 30, 2023 | Lung Cancer |
The first-generation lung cancer classification model based on gene expression data is already available for use within Qlucore Insights.
Read MorePosted by Chris Wolski | May 29, 2023 | Cancer |
Delays in cancer screening during the COVID-19 pandemic will likely cause a significant increase in cancer cases.
Read MorePosted by Melanie Hamilton-Basich | May 26, 2023 | Hematology & Serology, Lung Cancer |
A new class of blood-based biomarkers could be developed into improved or orthogonal tests for predicting tumor responses to treatment.
Read MorePosted by Chris Wolski | May 25, 2023 | Lung Cancer |
OncoHost will give a poster presentation demonstrating the accuracy of its PROphet biomarker model at the upcoming 2023 ASCO Annual Meeting.
Read More